JP2017525740A5 - - Google Patents

Download PDF

Info

Publication number
JP2017525740A5
JP2017525740A5 JP2017512677A JP2017512677A JP2017525740A5 JP 2017525740 A5 JP2017525740 A5 JP 2017525740A5 JP 2017512677 A JP2017512677 A JP 2017512677A JP 2017512677 A JP2017512677 A JP 2017512677A JP 2017525740 A5 JP2017525740 A5 JP 2017525740A5
Authority
JP
Japan
Prior art keywords
group
heterocyclyl
optionally substituted
carbocyclyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017512677A
Other languages
English (en)
Japanese (ja)
Other versions
JP6814730B2 (ja
JP2017525740A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/048174 external-priority patent/WO2016036873A1/en
Publication of JP2017525740A publication Critical patent/JP2017525740A/ja
Publication of JP2017525740A5 publication Critical patent/JP2017525740A5/ja
Application granted granted Critical
Publication of JP6814730B2 publication Critical patent/JP6814730B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017512677A 2014-09-05 2015-09-02 治療用化合物およびその使用 Expired - Fee Related JP6814730B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462046770P 2014-09-05 2014-09-05
US62/046,770 2014-09-05
PCT/US2015/048174 WO2016036873A1 (en) 2014-09-05 2015-09-02 Therapeutic compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2017525740A JP2017525740A (ja) 2017-09-07
JP2017525740A5 true JP2017525740A5 (cg-RX-API-DMAC7.html) 2018-10-11
JP6814730B2 JP6814730B2 (ja) 2021-01-20

Family

ID=54140703

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512677A Expired - Fee Related JP6814730B2 (ja) 2014-09-05 2015-09-02 治療用化合物およびその使用

Country Status (5)

Country Link
US (1) US10358437B2 (cg-RX-API-DMAC7.html)
EP (1) EP3189046B1 (cg-RX-API-DMAC7.html)
JP (1) JP6814730B2 (cg-RX-API-DMAC7.html)
CN (1) CN107074823B (cg-RX-API-DMAC7.html)
WO (1) WO2016036873A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016036954A1 (en) 2014-09-05 2016-03-10 Genentech, Inc. Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer
JP6659703B2 (ja) 2015-01-09 2020-03-04 ジェネンテック, インコーポレイテッド ピリダジノン誘導体および癌の処置におけるそれらの使用
CN110117271A (zh) * 2018-02-06 2019-08-13 中国科学院上海药物研究所 四氢异喹啉类化合物、其制备方法、包含此类化合物的药物组合物及其用途
TWI840423B (zh) * 2018-10-12 2024-05-01 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
US20220289711A1 (en) * 2019-07-31 2022-09-15 Foghorn Therapeutics Inc. Compounds and uses thereof
KR102085758B1 (ko) * 2019-08-05 2020-03-06 연세대학교 산학협력단 히스톤 아세틸트렌스퍼라제 p300 억제용 신규 화합물 및 이를 포함하는 항섬유화 조성물
WO2021050945A1 (en) 2019-09-12 2021-03-18 Terns, Inc. Thyroid hormone receptor beta agonist compounds
CN120112525A (zh) 2022-09-02 2025-06-06 奥龙医疗公司 用于治疗增殖性病症的作为kat2降解剂的哒嗪酮衍生物
TW202506131A (zh) 2023-04-07 2025-02-16 美商拓臻製藥公司 GLP-1R及THRβ激動劑之組合以及其使用方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
WO1991003489A1 (en) 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
FR2707294B1 (fr) * 1993-07-06 1995-09-29 Pf Medicament Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine.
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
DE69507956T2 (de) 1994-07-21 1999-09-09 Akzo Nobel N.V. Zyklische keton peroxyde zubereitungen
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
WO1996030347A1 (en) 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
DE69619114T2 (de) 1995-07-06 2002-10-02 Novartis Ag, Basel Pyrolopyrimidine und verfahren zu ihrer herstellung
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ATE213730T1 (de) 1996-04-12 2002-03-15 Warner Lambert Co Umkehrbare inhibitoren von tyrosin kinasen
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
PT980244E (pt) 1997-05-06 2003-10-31 Wyeth Corp Utilizacao de compostos de quinazolina para o tratamento da doenca policistica renal
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
CN1278176A (zh) 1997-11-06 2000-12-27 美国氰胺公司 喹唑啉衍生物作为用于治疗结肠息肉的酪氨酸激酶抑制剂的应用
AU763626B2 (en) 1998-11-19 2003-07-31 Warner-Lambert Company N-(4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl- propoxy)-quinazolin-6-yl)-acrylamide, an irreversible inhibitor of tyrosine kinases
EA014955B1 (ru) 2004-06-30 2011-04-29 Янссен Фармацевтика Н. В. Производные фталазина в качестве ингибиторов parp
FR2882750B1 (fr) * 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
FR2933979B1 (fr) * 2008-07-15 2012-08-24 Pf Medicament Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
CN102918031A (zh) * 2010-05-28 2013-02-06 通用电气健康护理有限公司 放射标记的化合物及其方法
LT2794618T (lt) * 2011-12-20 2017-02-27 Sanofi Izotiazolpiridin-2-karboksamidai ir jų panaudojimas kaip vaistų
UY35103A (es) 2012-10-29 2014-05-30 Glaxo Group Ltd Compuestos de cefem 2-sustituidos
US9200005B2 (en) 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
JP2016519672A (ja) 2013-03-15 2016-07-07 ジェネンテック, インコーポレイテッド ブロモドメイン含有タンパク質brd7およびbrd9の阻害によるth2媒介性疾患の治療
WO2016036954A1 (en) 2014-09-05 2016-03-10 Genentech, Inc. Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer
JP6659703B2 (ja) 2015-01-09 2020-03-04 ジェネンテック, インコーポレイテッド ピリダジノン誘導体および癌の処置におけるそれらの使用

Similar Documents

Publication Publication Date Title
JP2017525740A5 (cg-RX-API-DMAC7.html)
JP2017526696A5 (cg-RX-API-DMAC7.html)
JP2017533250A5 (cg-RX-API-DMAC7.html)
JP2018510851A5 (cg-RX-API-DMAC7.html)
JP2019516757A5 (cg-RX-API-DMAC7.html)
JP2017530176A5 (cg-RX-API-DMAC7.html)
JP2019516759A5 (cg-RX-API-DMAC7.html)
JP2017537100A5 (cg-RX-API-DMAC7.html)
JP2017533249A5 (cg-RX-API-DMAC7.html)
JP2018501287A5 (cg-RX-API-DMAC7.html)
JP2017530984A5 (cg-RX-API-DMAC7.html)
JP2017533248A5 (cg-RX-API-DMAC7.html)
JP2010522194A5 (cg-RX-API-DMAC7.html)
JP2019529444A5 (cg-RX-API-DMAC7.html)
JP2018505169A5 (cg-RX-API-DMAC7.html)
JP2015500209A5 (cg-RX-API-DMAC7.html)
JP2013536193A5 (cg-RX-API-DMAC7.html)
JP2018507191A5 (cg-RX-API-DMAC7.html)
JP2016510748A5 (cg-RX-API-DMAC7.html)
JP2016513137A5 (cg-RX-API-DMAC7.html)
JP2012526143A5 (cg-RX-API-DMAC7.html)
JP2017500334A5 (cg-RX-API-DMAC7.html)
JP2017510641A5 (cg-RX-API-DMAC7.html)
JP2007523177A5 (cg-RX-API-DMAC7.html)
AU2016284816A1 (en) Pharmaceutical co-crystal composition and use thereof